A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Animals
COVID-19
/ immunology
COVID-19 Vaccines
/ administration & dosage
Cricetinae
Disease Models, Animal
Female
Genetic Vectors
/ genetics
Glycosylation
Macaca fascicularis
/ genetics
Male
Mesocricetus
/ genetics
Mice
SARS-CoV-2
/ immunology
Safety
Spike Glycoprotein, Coronavirus
/ chemistry
Vaccines, Attenuated
/ administration & dosage
Yellow Fever Vaccine
/ genetics
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
15
07
2020
accepted:
24
11
2020
pubmed:
2
12
2020
medline:
17
2
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response
Identifiants
pubmed: 33260195
doi: 10.1038/s41586-020-3035-9
pii: 10.1038/s41586-020-3035-9
doi:
Substances chimiques
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Attenuated
0
Yellow Fever Vaccine
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
320-325Références
WHO. Draft landscape of COVID-19 candidate vaccines, https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines (accessed 4 November 2020).
Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).
pubmed: 33203860
pmcid: 7672082
Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182, 73–84.e16 (2020).
pubmed: 32425270
pmcid: 7231725
Barrett, A. D. & Teuwen, D. E. Yellow fever vaccine – how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21, 308–313 (2009).
pubmed: 19520559
Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62–73 (2010).
pubmed: 19966816
Bonaldo, M. C., Sequeira, P. C. & Galler, R. The yellow fever 17D virus as a platform for new live attenuated vaccines. Hum. Vaccin. Immunother. 10, 1256–1265 (2014).
pubmed: 24553128
pmcid: 4896586
Afonja, O. et al. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Rev. Hematol. 9, 1151–1164 (2016).
pubmed: 27841041
ICH. Quality guidelines for pharmaceutical quality based on Good Manufacturing Practice (GMP); Quality of Biotechnological Products (Q5A–Q5E), https://www.ich.org/page/quality-guidelines (accessed 4 November 2020).
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
pubmed: 32155444
pmcid: 7102599
Du, L. et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009).
pubmed: 19198616
pmcid: 2750777
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
pubmed: 32075877
pmcid: 7164637
Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020).
pubmed: 32731257
pmcid: 7581548
Ferguson, M., Shin, J., Knezevic, I., Minor, P. & Barrett, A. WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines, Geneva, Switzerland, 13–14 May 2009. Vaccine 28, 8236–8245 (2010).
pubmed: 21055492
pmcid: 7131007
Kum, D. B. et al. Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerg. Microbes Infect. 8, 1734–1746 (2019).
pubmed: 31797751
pmcid: 6896426
Mishra, N. et al. A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies. MBio 11, e02494-19 (2020).
pubmed: 32265332
pmcid: 7157777
Thomas, R. E., Lorenzetti, D. L., Spragins, W., Jackson, D. & Williamson, T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am. J. Trop. Med. Hyg. 86, 359–372 (2012).
pubmed: 22302874
pmcid: 3269291
Rafferty, E., Duclos, P., Yactayo, S. & Schuster, M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine 31, 5798–5805 (2013).
pubmed: 24079979
Mateo, R. I. et al. Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamsters. Am. J. Trop. Med. Hyg. 77, 919–924 (2007).
pubmed: 17984354
Erickson, A. K. & Pfeiffer, J. K. Spectrum of disease outcomes in mice infected with YFV-17D. J. Gen. Virol. 96, 1328–1339 (2015).
pubmed: 25646269
pmcid: 4635484
Watson, A. M., Lam, L. K., Klimstra, W. B. & Ryman, K. D. The 17D–204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 12, e1005786 (2016).
pubmed: 27463517
pmcid: 4962991
Martins, R. M. et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum. Vaccin. Immunother. 9, 879–888 (2013).
pubmed: 23364472
pmcid: 3903908
Tesh, R. B., Travassos da Rosa, A. P., Guzman, H., Araujo, T. P. & Xiao, S. Y. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg. Infect. Dis. 8, 245–251 (2002).
pubmed: 11927020
pmcid: 2732478
Chan, J. F.-W. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428–2446 (2020).
pubmed: 32215622
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020).
pubmed: 32408338
pmcid: 7394720
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).
pubmed: 32571934
pmcid: 7368255
Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).
pubmed: 32303590
pmcid: 7164679
van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578–582 (2020).
pubmed: 32731258
pmcid: 8436420
Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811 (2020).
pubmed: 32434945
pmcid: 7243363
Staples, J. E., Barrett, A. D. T., Wilder-Smith, A. & Hombach, J. Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. npj Vaccines 5, 54 (2020).
pubmed: 32655896
pmcid: 7338446
Casey, R. M. et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report. N. Engl. J. Med. 381, 444–454 (2019).
pubmed: 29443626
Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828–842.e16 (2020).
pubmed: 32645326
pmcid: 7311918
Meier, K. C., Gardner, C. L., Khoretonenko, M. V., Klimstra, W. B. & Ryman, K. D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 5, e1000614 (2009).
pubmed: 19816561
pmcid: 2749449
Erickson, A. K. & Pfeiffer, J. K. Dynamic viral dissemination in mice infected with yellow fever virus strain 17D. J. Virol. 87, 12392–12397 (2013).
pubmed: 24027319
pmcid: 3807901
Kum, D. B. et al. A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. npj Vaccines 3, 56 (2018).
pubmed: 30564463
pmcid: 6292895
Channappanavar, R. et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19, 181–193 (2016).
pubmed: 26867177
pmcid: 4752723
Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–539 (2017).
pubmed: 28466096
pmcid: 7079893
Page, C. et al. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J. Virol. 86, 13334–13349 (2012).
pubmed: 23015710
pmcid: 3503056
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e15 (2020).
pubmed: 32473127
pmcid: 7237901
Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971–977.e3 (2020).
pubmed: 32413330
pmcid: 7196424
Appaiahgari, M. B. & Vrati, S. IMOJEV
pubmed: 21105774
Guy, B. et al. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev. Vaccines 16, 671–684 (2017).
Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).
pubmed: 32376603
Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713–721.e9 (2020).
pubmed: 32778225
pmcid: 7275151
Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572–577 (2020).
pubmed: 32726802
Feng, L. et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat. Commun. 11, 4207 (2020).
pubmed: 32826924
pmcid: 7442803
Erasmus, J. H. et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med. 12, eabc9396 (2020).
pubmed: 32690628
WHO. International Travel and Health. Yellow fever, https://www.who.int/ith/vaccines/yf/en/ (accessed 4 November 2020).
Lambert, P. H. et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine 38, 4783–4791 (2020).
pubmed: 32507409
Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).
pmcid: 6478436
Smatti, M. K., Al Thani, A. A. & Yassine, H. M. Viral-induced enhanced disease illness. Front. Microbiol. 9, 2991 (2018).
pubmed: 30568643
pmcid: 6290032
Lindenbach, B. D. & Rice, C. M. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 71, 9608–9617 (1997).
pubmed: 9371625
pmcid: 230269
Buchholz, U. J., Finke, S. & Conzelmann, K. K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251–259 (1999).
pubmed: 9847328
pmcid: 103829
Dallmeier, K. & Neyts, J. Simple and inexpensive three-step rapid amplification of cDNA 5′ ends using 5′ phosphorylated primers. Anal. Biochem. 434, 1–3 (2013).
pubmed: 23123427
pmcid: 3562438
Sharma, S. et al. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine. Hum. Vaccin. Immunother. 16, 2196–2203 (2020).
pubmed: 32574095
pmcid: 7553677
Bredenbeek, P. J. et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299–304 (2006).
pubmed: 16412488
Conceição-Neto, N. et al. Modular approach to customise sample preparation procedures for viral metagenomics: a reproducible protocol for virome analysis. Sci. Rep. 5, 16532 (2015).
pubmed: 26559140
pmcid: 4642273
Conceição-Neto, N., Yinda, K. C., Van Ranst, M. & Matthijnssens, J. NetoVIR: modular approach to customize sample preparation procedures for viral metagenomics. Methods Mol. Biol. 1838, 85–95 (2018).
pubmed: 30128991
Müller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918–1921 (1994).
pubmed: 8009221
van den Broek, M. F., Müller, U., Huang, S., Zinkernagel, R. M. & Aguet, M. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148, 5–18 (1995).
pubmed: 8825279
Fan, Z. et al. Efficient gene targeting in golden Syrian hamsters by the CRISPR/Cas9 system. PLoS ONE 9, e109755 (2014).
pubmed: 25299451
pmcid: 4192357
Siddharthan, V. et al. Zika virus infection of adult and fetal STAT2 knock-out hamsters. Virology 507, 89–95 (2017).
pubmed: 28431283
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).
pmcid: 6988269
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2
pubmed: 11846609
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
Vandeghinste, B. et al. Iterative CT reconstruction using shearlet-based regularization. IEEE Trans. Nucl. Sci. 60, 3305–3317 (2012).
Vande Velde, G. et al. Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume. Dis. Model. Mech. 9, 91–98 (2016).
pubmed: 26563390
pmcid: 4728330
Berghen, N. et al. Radiosafe micro-computed tomography for longitudinal evaluation of murine disease models. Sci. Rep. 9, 17598 (2019).
pubmed: 31772203
pmcid: 6879529
Kaptein, S. J. et al. Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine. Preprint at https://doi.org/10.1101/2020.06.19.159053 (2020).
Geisinger, J. M., Turan, S., Hernandez, S., Spector, L. P. & Calos, M. P. In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining. Nucleic Acids Res. 44, e76 (2016).
pubmed: 26762978
pmcid: 4856974
Whitt, M. A. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365–374 (2010).
pubmed: 20709108
pmcid: 2956192
Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS ONE 6, e25858 (2011).
pubmed: 21998709
pmcid: 3187809
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
pubmed: 32142651
pmcid: 7102627
Fukushi, S. et al. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J. Gen. Virol. 86, 2269–2274 (2005).
pubmed: 16033974
Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2511 (2020).
pubmed: 32409714
pmcid: 7224291
Kleine-Weber, H. et al. Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J. Virol. 93, e01381-18 (2019).
pubmed: 30404801
pmcid: 6321919
Op De Beeck, A., Rouillé, Y., Caron, M., Duvet, S. & Dubuisson, J. The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals. J. Virol. 78, 12591–12602 (2004).
pubmed: 15507646
pmcid: 525104
Bonaldo, M. C. et al. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol. J. 4, 115 (2007).
pubmed: 17971212
pmcid: 2173888
Barban, V. et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 25, 2941–2950 (2007).
pubmed: 16914238